Ipsen

From Wikipedia, the free encyclopedia

Ipsen S.A.
TypePublic
Euronext: IPN
CAC Mid 60 Component
ISINFR0010259150
IndustryPharmaceutical
Founded1929
HeadquartersParis, France
Key people
Marc de Garidel (Non-executive Chairman)
David Loew (Chief Executive Officer)
Products 
Number of employees
5,700
Websitewww.ipsen.com

Ipsen is a French pharmaceutical company headquartered in Paris, France.[1] It is specialized in oncology, neuroscience and rare diseases.[1] It is publicly traded on the Euronext Paris as part of the SBF 120 index (2005).[1][2]

Ipsen, founded by Henri Beaufour in 1929, has 5,700 employees worldwide, and markets 20 drugs in 115 countries. The Beaufour family owns 57% of its shares and 73% of its voting rights,[3] and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.[4]

Overview[]

In 1954, the group launched Citrate de Betaïne which is used in the symptomatic treatment of dyspepsies. The two sons of Henri Beaufour, Albert and Gérard Beaufour, joined the company.[5]

In 1961, the first factory was opened in Dreux.[6]

In 1976, a research center was started in Milford in Massachusetts in the United States.[7] In 1977, the Smecta was launched.[5]

In 1983, the Ipsen Foundation was created, under the aegis of the Fondation de France.[8]

In 1992, Ipsen opened a subsidiary in China[9] and later, in 1994, in Russia.[citation needed]

In 2007, the group established a partnership with Galderma.[citation needed]

In 2013, Ipsen acquired the British company Syntaxin.[10]

In 2014, a laboratory was created with the CNRS in association with the French Alternative Energies and Atomic Energy Commission and the University of Rennes 1.[11]

In February 2015, the company announced Canbex Therapeutics $6.8 million upfront upon completion of a Phase IIA study of Canbex's lead multiple sclerosis compound, VSN16R.[12]

in October 2016, European Commission approved Ipsen's Cabometyx (Cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.[13]

The CABOSUN study, presented at the European Society for Medical Oncology (ESMO) 2016 congress, showed Cabometyx (Cabozantinib) can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma (RCC).[14]

In January 2017, Ipsen acquired some assets of Merrimack Pharmaceuticals, including Onivyde.[15]

In February 2019, Ipsen announced it would acquire Clementia Pharmaceuticals, a biopharmaceutical company specialized in rare bone diseases, for $1.3 billion.[16] This acquisition is the largest in the history of Ipsen. In April 2019, Ipsen announced the deal was finalized.[17]

In 2019, Ipsen spent close to €388.8 million—15.1% of consolidated sales—on research and development.[citation needed]

In July 2020, David Loew was appointed the General Manager and CEO in Ipsen.[18]

Research and development[]

In 2019, Ipsen's R&D expenditure totaled close to €388.8 million, representing more than 15.1% of group sales.[citation needed] Ipsen's main research and development centers are located in Cambridge (Massachusetts, United States), Milton Park / Oxford (United Kingdom) and Les Ulis Courtaboeuf (France).[citation needed]

References[]

  1. ^ Jump up to: a b c "Profile & key figures". Ipsen. Archived from the original on 1 February 2013.[self-published source]
  2. ^ "Ipsen, "plus actif que jamais", prévoit des opérations de M&A". Investir (in French). Retrieved 9 June 2021.
  3. ^ 2015 Registration Document (PDF) (Report). 29 March 2016. Archived from the original (PDF) on 4 June 2016.[self-published source]
  4. ^ Challenges wealth ranking. Challenges.fr.
  5. ^ Jump up to: a b "Société d'Histoire de la Pharmacie – Le nouveau site de la SHP !" (in French). Retrieved 9 June 2021.
  6. ^ France, Centre (17 February 2015). "Ipsen a engagé plus de 40 millions d'euros d'investissement entre 2012 et 2016". www.lechorepublicain.fr. Retrieved 9 June 2021.
  7. ^ pharma, Industrie (16 May 2005). "Résultats : Ipsen veut poursuivre sa politique d'alliances" (in French). Cite journal requires |journal= (help)
  8. ^ "Homepage Ipsen". Fondation Ipsen. Retrieved 9 June 2021.
  9. ^ "France Chine : Informations, culture et tourisme en Chine". France Chine (in French). Retrieved 9 June 2021.
  10. ^ "Ipsen s'offre le spécialiste britannique des toxines botuliques Syntaxin" (in French). 15 July 2013. Cite journal requires |journal= (help)
  11. ^ "Ipsen - CNRS Laboratoire Commun" (PDF).
  12. ^ "Ipsen Gains Option to Buy Canbex Therapeutics for $6.8M+". 24 February 2015.
  13. ^ [1] European Commission approves Ipsen’s Cabometyx for treatment of advanced renal cell carcinoma
  14. ^ [2] Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx
  15. ^ Reuters Staff (9 January 2017). "France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 billion deal". Reuters. Retrieved 9 June 2021.
  16. ^ "Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3..." 25 February 2019 – via uk.reuters.com.
  17. ^ "Ipsen completes acquisition of Clementia Pharmaceuticals". 18 April 2019 – via Pharmacy Business.
  18. ^ "Ipsen mise sur l'innovation externe pour assurer sa croissance". Les Echos (in French). 1 December 2020. Retrieved 9 June 2021.

External links[]

Retrieved from ""